33 results about "Premalignant Neoplasm" patented technology

This invention discloses a composite nanodelivery system encapsulated in a fusion membrane, its preparation method, and its applications. The nanodelivery system comprises a Ti3C2 / TiO2 / CuInS2 composite material, oxaliplatin loaded thereon, and a fusion membrane encapsulating the outer layer; the fusion membrane is formed by the fusion of Fusobacterium nucleatum extravesicles and M1 macrophage membranes. This invention also discloses a method for preparing the nanodelivery system, including the steps of preparing the Ti3C2 / TiO2 / CuInS2 composite material, preparing the fusion membrane, loading oxaliplatin, and encapsulating it in the fusion membrane. The nanodelivery system prepared by this invention exhibits pH-responsive drug release characteristics, generating H2S in the tumor microenvironment and H2 under light irradiation, while also possessing photocatalytic activity. This invention combines chemotherapy, photoelectrocatalytic therapy, and the regulation of multiple active substances, and can be used to prepare drugs for treating malignant tumors of the digestive system.

This invention discloses a PROTAC chimera for targeted degradation of ALKBH5, its preparation method, and its applications. The structural formula of the PROTAC chimera is shown in Formula I. The PROTAC chimera provided by this invention achieves specific ubiquitination modification and proteasome-dependent degradation of the ALKBH5 protein, completely eliminating the target protein function from its source. This invention overcomes the inherent limitations of traditional small molecule inhibitors, which can only reversibly block ALKBH5 enzyme activity, cannot eliminate the target protein, easily induce compensatory upregulation of the target protein, and develop drug resistance. It provides a novel and precise targeted therapy strategy for ALKBH5-driven malignant tumors.

This invention discloses a radioactive molecular probe for targeting CSPG4 / NG2, its preparation method, and its application. The radioactive molecular probe comprises the structure shown in Formula I or Formula II. The technical solution of this invention uses a radioactive molecular probe to specifically recognize CSPG4 / NG2 in vivo through the target polypeptide portion, thereby achieving specific nuclear medicine positron emission tomography (PET) or single-photon emission computed tomography (SPECT) imaging diagnosis of CSPG4 / NG2 positive tumors or CSPG4 / NG2 positive lesions, such as autoimmune diseases and cardiovascular and cerebrovascular diseases, thereby realizing early diagnosis and efficacy evaluation of malignant tumors.

This invention provides a hypoxia-mediated mechanism of malignant tumor formation, a treatment simulation method, and a system, relating to the field of biomathematical modeling technology. The method includes: dividing the tumor into a core region and a peripheral region, defining the core differences between the two regions in their microenvironmental composition, and forming a conceptual interaction network; establishing a state variable system centered on the number of tumor cells, constructing a mathematical model integrating tumor core-periphery heterogeneity, hypoxia-mediated processes, and immunosuppression cycles; solving the mathematical model, calculating the changes of each state variable over time under different initial conditions or intervention parameters, and outputting simulation results characterizing tumor growth and the state of the immune microenvironment; this invention, through the multi-level regulation of cell proliferation, immunosuppression cycles, and angiogenesis signals by oxygen concentration gradients, more realistically reproduces the spatial heterogeneous growth dynamics of solid tumors in vivo, and simulates the formation and maintenance mechanism of a strong immunosuppressive state in the tumor core region.

This invention discloses a methylation marker for the differential diagnosis of malignant and benign breast tumors. The invention provides the application of the methylated SH3PXD2B gene as a marker in product preparation; the product is used for at least one of the following purposes: (1) distinguishing between benign and malignant breast tumors; (2) distinguishing between benign breast tumors and different subtypes or stages of malignant breast tumors; (3) distinguishing between different subtypes or stages of malignant breast tumors. This invention has significant scientific and clinical application value for differentiating between benign and malignant breast tumors, different subtypes or stages of malignant breast tumors, and guiding the development of reasonable clinical treatment plans.

The present invention provides an antitumor agent for treating a malignant tumor patient expressing EGFR having at least one mutation selected from the group consisting of L718X mutation in exon 18 and L792X mutation in exon 20, wherein X represents an arbitrary amino-acid residue, the antitumor agent comprising(S)—N-(4-amino-6-methyl-5-(quinolin-3-yl)-8.9-dihydropyrimido[5.4-b]indolizin-8-yl)acrylamide (Compound (A)) or a salt thereof.

FIELD: oncology.SUBSTANCE: used to treat malignant embryonic tumors. The method involves pharmacological inhibition of factors that support tumor growth. A progesterone receptor antagonist is administered and immunological activation of the body's response against progesterone-induced blocking factor (PIBF), placental growth factor (PIGF) and trophoblastic β 1-glycoprotein.EFFECT: increased treatment reliability due to a comprehensive and selective effect on the tumor, simultaneous influence on both the primary tumor site and metastases, a reduction in the likelihood of relapse due to the destruction of the tumor vascular network, and a reduction in the overall toxic load on the patient's body during treatment.7 cl, 1 tbl, 5 ex

The application discloses damaged mitochondria as a malignant tumor metastasis prediction marker, and an application and detection system thereof, and is used for solving the problems of lacking specific prediction indexes and efficient and feasible prediction means for predicting malignant tumor metastasis in the prior art. The application rapidly enriches mitochondria from a to-be-detected plasma sample, detects the concentration of the prediction marker damaged mitochondria, and predicts the malignant tumor metastasis risk of a patient corresponding to the to-be-detected plasma sample based on the concentration of the prediction marker damaged mitochondria, so that whether the tumor patient will have metastasis in the future can be simply, rapidly and accurately predicted.

The application discloses a novel radionuclide therapeutic drug targeting nucleolus DDX24 helicase and a preparation method and application thereof. 64 The Cu-DOTA-TDP-2 has good tumor targeting uptake specificity, and is expected to provide a precise molecular imaging method for esophageal squamous cell carcinoma and other DDX24 high-expression malignant tumors; the novel radionuclide targeted drug 177 The Lu-DOTA-TDP-2 has high radiochemical yield and specific activity, good chemical stability, high affinity for DDX24 helicase, and a simple and easy-to-operate preparation method, and can be used for the treatment of DDX24 high-expression malignant tumors; the novel radionuclide targeted drug 177 The Lu-DOTA-TDP-2 has excellent biological safety performance and good tumor inhibition effect in esophageal squamous cell carcinoma and other DDX24 high-expression malignant tumors.

The application belongs to the technical field of biological probes, and relates to a PD-L1 guided specific targeted CTC detection combined with tumor boundary distinguishing biological probe and a preparation method thereof. The PD-L1 guided specific targeted CTC detection combined with tumor boundary distinguishing biological probe comprises a core, a covalent organic framework and a PD-L1 antibody, the core comprises a superparamagnetic nanoparticle, the covalent organic framework is coated on the surface of the core, and the PD-L1 antibody is combined on the surface of the covalent organic framework. The PD-L1 guided specific targeted CTC detection combined with tumor boundary distinguishing biological probe prepared by the application can be transported into the body across the membrane, smoothly enter a PD-L1 positive malignant tumor lesion, and perform Raman imaging to microscopically distinguish the tumor boundary.

The present application relates to a kind of PROTAC compound targeted degradation CDK2 and its preparation method and application, provide a kind of PROTAC compound, can targeted degradation CDK2, compared with existing CDK2 inhibitor, the small molecule compound prepared by the present application can effectively induce the degradation of CDK2 protein in MCF-7 cell, with good inhibiting MCF-7 cell proliferation ability, show better treatment effect to breast cancer, have potential to become effective treatment mode for treating malignant tumor.

A gene delivery system and applications thereof in the technical field of biological medicines that is particularly useful in the preparation of drugs for treatment of tumors are disclosed. The gene delivery system and applications relate to technology for inducing the differentiation of malignant tumor cells into mature cells, in which regulating the expression of HNF4 alpha protein in the malignant tumor cells using messenger ribonucleic acid, the malignant phenotype of the malignant solid tumor cells is inhibited, and the effective treatment of the malignant solid tumors is achieved. The gene delivery system and applications are therefore applicable to a method of preparing a drug for treating malignant solid tumors and to a method of treating a patient having a malignant solid tumor.

The present application relates to the use of [10]-shogaol in the preparation of a medicament for preventing and / or treating tumors sensitive to ferroptosis. Specifically, the present application provides a method for screening ferroptosis inducers, comprising the following steps: taking cells sensitive to ferroptosis, applying a candidate compound to a test group, applying [10]-shogaol to a positive control group, applying [6]-shogaol to a non-ferroptosis inducer group, and not applying any compound to a blank control group; detecting the lipid peroxidation level in the cells of each group; comparing the lipid peroxidation levels of the test group and the other groups to detect whether the candidate compound is a ferroptosis inducer. The [10]-shogaol can effectively induce ferroptosis in various malignant tumor cells such as breast cancer, colorectal cancer, melanoma, etc., and the mechanism of action depends on the accumulation of lipid peroxidation, and this effect can be specifically blocked by ferroptosis inhibitors.

This invention belongs to the field of traditional Chinese medicine application technology and provides an application of a traditional Chinese medicine composition in the treatment of radiation-induced pneumonia. The traditional Chinese medicine composition is made from bamboo sap and *Trifolium repens*; the mass ratio of bamboo sap to *Trifolium repens* is (1-10):(1-10). Radiation-induced pneumonia refers to lung inflammation caused by radiotherapy for malignant tumors of the chest. The traditional Chinese medicine composition provided by this invention has the effects of clearing heat and detoxifying, resolving phlegm and dissipating nodules. It has a simple composition and high safety, providing a new option for the treatment of radiation-induced pneumonia.

The present invention relates to a PROTAC compound for targeted degradation of CDK2, a preparation method therefor and a use thereof, and provides a PROTAC compound that is capable of targeted degradation of CDK2. Compared with existing CDK2 inhibitors, the small-molecule compound prepared by the present invention can effectively induce the degradation of CDK2 protein in MCF-7 cells, exhibits good ability to inhibit the proliferation of MCF-7 cells, demonstrates favorable therapeutic effects against breast cancer, and has the potential to become an effective treatment modality for malignant tumors.

The present application relates to a kind of NAD (P) H response type diagnosis and treatment integrated boron medicine and its preparation method, the boron medicine with 10 B acetylacetone difluoroboric ester as mother nucleus, by introducing the cell nucleus target ability of N-containing or S-containing heterocyclic structure, simultaneously introduce the response unit that can specifically respond to high expression NAD (P) H in tumor microenvironment, activate fluorescence / photoacoustic dual-mode imaging signal, realize the visual positioning of tumor site.On this basis, the present application realizes three big core functions: one is through NAD (P) H response point light imaging, effectively reduce background signal interference;Two is by means of N or S atom and the combination of cell nucleus DNA / RNA, will 10 B be accurately delivered to nucleus, significantly improve BNCT killing efficiency;Three is under the guidance of imaging, thermal neutron irradiation is carried out, triggers 10 B (n, α) 7 Li nuclear fission reaction, finally realizes high-precision diagnosis and treatment integration.The preparation method of the boron medicine is also disclosed, can be used for preparing malignant tumor diagnosis and treatment drug, has good clinical application prospect.

This invention relates to the field of pharmaceutical technology, specifically disclosing a method for preparing and applying acid-sensitive environment-responsive PEGylated self-assembled micelles. The key technical points are as follows: the micelles are formed by the self-assembly of a 0831A-Hyd-mPEG conjugate in an aqueous solution. This conjugate is prepared through the following steps: first, monomethoxy polyethylene glycol (mPEG) is reacted with p-aldehyde benzoic acid to generate mPEG-CHO, which is then linked to 0831A (SKLB060-methionine) via an acylhydrazone bond; wherein the number-average molecular weight of mPEG is 2000; the average particle size of the micelles is approximately 157 nm, exhibiting significant pH-responsive drug release characteristics, with a cumulative drug release rate of 69.46±2.13% after 48 hours at pH 5.0, compared to only 22.94±0.67% at pH 7.4. The micelle structure of the present invention is well-defined and easy to prepare. It can effectively prolong the in vivo circulation time of the drug and significantly reduce its systemic toxicity while retaining the antitumor activity of 0831A. It is particularly suitable for preparing drugs for treating malignant tumors such as colorectal cancer.

KLRB1 binding agents (in particular anti-KLRB1-antibodies and antigen binding portion thereof) with increased humanness and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells, (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, iNKT, peTh2, ILC2, ILC3, NK cells, and / or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.

Described herein are methods and compositions for treating solid or liquid B-cell malignancies using a two-component platform based on morpholino oligonucleotide-linked conjugates to target B-cells and effector cells. The methods described herein may involve two distinct dosing approaches tailored to the type of B-cell malignancy being treated. In some embodiments, solid B-cell tumors are treated using a premixed assembly dosing regimen. In some embodiments, liquid B-cell tumors are treated using a consecutive dosing regimen.

The application discloses an in-vivo drug delivery device, and relates to the technical field of medical intervention instruments.The main body of the in-vivo drug delivery device is made of PEG powder and 50:50 proportion of PLGA medical degradable high-molecular material, is formed through a salt pore forming process, and is internally provided with uniform and slow-release pores.The size can be adapted to different target blood vessels, the device is implanted into a lesion blood-supplying blood vessel through an intervention mode, and the drug loading formula can be flexibly adjusted according to diseases, and heparin and dexamethasone are added to prevent thrombosis and suppress inflammation.The in-vivo drug delivery device can realize 1-3 month controllable slow release of drugs, accurately delivers the drugs to a lesion at a high concentration, solves the problems of poor curative effect and large toxic and side effects of systemic drug delivery, is suitable for local treatment of malignant tumors and refractory chronic inflammation, and finally is completely degraded without residue, and does not need secondary operation.The in-vivo drug delivery device has the advantages of simple structure, flexible drug loading, good biocompatibility, wide clinical application range, and effectively makes up for the technical defects of existing local drug delivery devices.

Provided are a pharmaceutical combination and a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable form thereof and at least one other anticancer agent, and use thereof in the preparation of a medicine for treating a malignant tumor disease. The other anticancer agent is a CDK inhibitor or a pharmaceutically acceptable salt thereof (such as palbociclib), lenvatinib or a pharmaceutically acceptable salt thereof, sorafenib or a pharmaceutically acceptable salt thereof, or any combination of the above.

The application discloses a PROTAC compound with a structure of formula I and application of the PROTAC compound in preparation of a pharmaceutical preparation for preventing or treating diseases caused by mediation of a T cell receptor signal path related protein (including HPK1, LCK, GLK, PCKθ and ITK proteins), such as a malignant tumor.

The application discloses a breast cancer neoadjuvant therapy prognosis multi-modal multi-task probability prediction method and system, and steps are as follows: using training data composed of breast DCE-MRI images and segmentation images of a plurality of breast cancer patients after various neoadjuvant therapies, and clinical information, radiology image reports, pathological reports and case information to perform breast cancer NAT prognosis multi-modal multi-task probability prediction training on a deep learning model; then using deep learning to analyze breast DCE-MRI images and segmentation images matched with the breast DCE-MRI images of a patient to be measured, and clinical information, radiology image reports, pathological reports and case information, generate and output pCR, DFS and OS prediction results of various different NAT schemes, risk probability and recurrence probability evaluation results of breast cancer metastasis to different organs, and benign and malignant tumor type and BI-RADS level identification results. The application can significantly improve the accuracy and comprehensiveness of NAT prognosis evaluation.

The present application relates to the field of biological medicine, and particularly relates to a kind of targeting CD19 nanobody and its preparation method and application.The present application provides a kind of nanobody targeting CD19, nucleic acid substance encoding the above-mentioned single domain antibody, corresponding expression vector and the host cell capable of expressing the nanobody targeting CD19.The nanobody provided by the present application has excellent specific CD19 binding capacity, and the nanobody affinity can reach 3.855x10 ‑9 ‌, show that the nanobody provided by the present application has highly specific binding activity, and has important application value in the treatment of B cell malignant tumor.

Disclosed herein are methods for treating a hematologic malignancy (e.g., acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphoblastic leukemia (ALL)), using an anti-Galectin-9 antibody (e.g., G9.2-17(IgG4). In some embodiments, the anti-Galectin-9 antibody is used as a monotherapy.

The present invention relates to the field of biotechnology, medicine, in particular, oncology and pharmaceuticals, and is directed to ready-to-use dosage forms of a medicinal product for combination gene-directed enzyme prodrug therapy—immune therapy of human solid malignant neoplasms.Two variants of two-component dosage forms of the medicinal product are proposed. In the first variant, the composition of the medicinal product includes the first and second containers, the first container containing the first component containing the pCMV-HSVtk-hGM-CSF therapeutic plasmid DNA in a therapeutically effective amount in the form of a frozen aqueous solution, and the second container containing the second component containing the polyethyleneimine-polyethylene glycol-TAT peptide block copolymer in a therapeutically effective amount in the form of a frozen aqueous solution. A ready-to-use solution for injection, intended for administration to a patient, is prepared ex tempore by thawing the referenced two components and mixing them.In the second variant, the composition of the medicinal product includes the first and second containers, the first container containing the first component containing the pCMV-HSVtk-hGM-CSF therapeutic plasmid DNA in a therapeutically effective amount in the form of a lyophilisate, and the second container containing the second component containing the polyethyleneimine-polyethylene glycol-TAT peptide block copolymer in a therapeutically effective amount in the form of a frozen aqueous solution. A ready-to-use solution for injection intended for administration to a patient is prepared ex tempore by reconstituting the first component by adding water, thawing the second component and mixing them.The proposed dosage forms can be used for the treatment of human solid malignant neoplasms. The two proposed dosage forms demonstrate high stability and retain their therapeutic efficacy for at least 18 months.

The present invention relates to a pharmaceutical composition useful for preventing or treating malignant tumors and, to a composition for preventing or treating malignant neoplasm, comprising, as an active ingredient, at least one selected from the group consisting of a compound represented by chemical formula (1), a pharmaceutically acceptable salt, a hydrate, a solvate, and a prodrug of the compound, and a combination thereof.

An ophthalmic formulation, its preparation method and use. The ophthalmic formulation comprises a protein tyrosine kinase inhibitor compound. The protein tyrosine kinase inhibitor is used for treating a protein tyrosine kinase-mediated proliferative disease or symptom, such as an eye disease and a malignant tumor accompanied by pathological neovascularization, retinal ischemia, retinal edema, diabetic retinopathy, etc. The formulation can improve the solubility of the compound, achieve a clear solution or a state close to a clear solution, has the potential to prolong the residence time of the compound on the ocular surface, improve the exposure of the ocular fundus tissue, and improve the bioavailability.

Devices, systems and methods are provided to treat damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) by delivering specialized pulsed electric field (PEF) energy to target tissue areas. The energy is delivered in a manner so as to be non-thermal (i.e. below a threshold for causing thermal ablation). Consequently, when extracellular matrices present, the extracellular matrices are preserved, and the targeted tissue maintains its structural architecture including blood vessels and lymphatics. Thus, sensitive structures, such as biological lumens, blood vessels, nerves, etc, are preserved which are critical to maintaining the integrity and functionality of the tissue. The energy is delivered with the use of systems and devices advantageously designed for superior access to target tissue throughout the body, particularly in locations previously considered inaccessible to percutaneous approaches.

This invention discloses a fluorine-nitrogen co-doped carbon dot, its preparation method, and its applications. The fluorine-nitrogen co-doped carbon dot is a nanoparticle constructed using a one-step hydrothermal synthesis method with fluorine-containing and nitrogen-containing precursors. The nanoparticle is spherical with a particle size of 5 nm, and its surface is rich in carboxyl, amino, and hydroxyl functional groups. Its fluorescence quantum yield is not less than 20%, and its emission wavelength is in the 500-550 nm range. It has the characteristic of targeting the H3K36me2 histone modification in tumor cell nuclei, and can achieve specific labeling of tumor cells within 5 minutes. The enrichment intensity in tumor tissue is more than 2.72 times that in normal tissue. The fluorine-nitrogen co-doped carbon dot of this invention is expected to serve as a novel fluorescent labeling probe for tumor identification and imaging, contributing to the early and accurate diagnosis of malignant tumors. It has multiple advantages such as speed, accuracy, safety, and visualization, and has broad application prospects in tumor pathology identification and intraoperative navigation.